Latest Insider Transactions at Novo Cure LTD (NVCR)
This section provides a real-time view of insider transactions for Novo Cure LTD (NVCR). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of NovoCure Ltd to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of NovoCure Ltd's insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Mar 04
2021
|
Frank X Leonard EVP, Pres., Novocure Oncology |
SELL
Open market or private sale
|
Direct |
567
-0.62%
|
$77,679
$137.55 P/Share
|
|
Mar 04
2021
|
Todd Christopher Longsworth General Counsel |
SELL
Open market or private sale
|
Direct |
3,084
-4.21%
|
$422,508
$137.55 P/Share
|
|
Mar 04
2021
|
Wilhelmus Cm Groenhuysen Chief Operating Officer |
SELL
Open market or private sale
|
Direct |
3,854
-2.4%
|
$527,998
$137.55 P/Share
|
|
Mar 04
2021
|
Pritesh Shah Chief Growth Officer |
SELL
Open market or private sale
|
Direct |
2,658
-2.64%
|
$364,146
$137.55 P/Share
|
|
Mar 04
2021
|
Ely Benaim Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
1,888
-4.96%
|
$258,656
$137.55 P/Share
|
|
Mar 03
2021
|
Pritesh Shah Chief Growth Officer |
SELL
Open market or private sale
|
Direct |
2,174
-2.11%
|
$326,100
$150.78 P/Share
|
|
Mar 03
2021
|
Ely Benaim Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
3,475
-8.37%
|
$521,250
$150.78 P/Share
|
|
Mar 03
2021
|
Ely Benaim Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
3,475
+7.72%
|
$239,775
$69.37 P/Share
|
|
Mar 02
2021
|
Todd Christopher Longsworth General Counsel |
BUY
Grant, award, or other acquisition
|
Direct |
10,342
+12.38%
|
-
|
|
Mar 02
2021
|
Todd Christopher Longsworth General Counsel |
SELL
Open market or private sale
|
Direct |
2,355
-3.61%
|
$357,960
$152.05 P/Share
|
|
Mar 02
2021
|
Pritesh Shah Chief Growth Officer |
BUY
Grant, award, or other acquisition
|
Direct |
10,886
+9.57%
|
-
|
|
Mar 02
2021
|
Pritesh Shah Chief Growth Officer |
SELL
Open market or private sale
|
Direct |
912
-0.98%
|
$138,624
$152.05 P/Share
|
|
Mar 02
2021
|
Wilhelmus Cm Groenhuysen Chief Operating Officer |
BUY
Grant, award, or other acquisition
|
Direct |
12,519
+7.23%
|
-
|
|
Mar 02
2021
|
Wilhelmus Cm Groenhuysen Chief Operating Officer |
SELL
Open market or private sale
|
Direct |
2,392
-1.59%
|
$363,584
$152.05 P/Share
|
|
Mar 02
2021
|
Ashley Cordova Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
10,886
+22.21%
|
-
|
|
Mar 02
2021
|
Ashley Cordova Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
428
-1.55%
|
$65,056
$152.05 P/Share
|
|
Mar 02
2021
|
Ely Benaim Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
8,709
+18.62%
|
-
|
|
Mar 02
2021
|
Uri Weinberg Chief Innovation Officer |
BUY
Grant, award, or other acquisition
|
Direct |
8,709
+19.35%
|
-
|
|
Mar 02
2021
|
Frank X Leonard EVP, Pres., Novocure Oncology |
BUY
Grant, award, or other acquisition
|
Direct |
8,709
+8.7%
|
-
|
|
Mar 02
2021
|
Frank X Leonard EVP, Pres., Novocure Oncology |
SELL
Open market or private sale
|
Direct |
430
-0.52%
|
$65,360
$152.05 P/Share
|
|
Mar 02
2021
|
Martin J. Madden |
BUY
Grant, award, or other acquisition
|
Indirect |
111
+20.98%
|
-
|
|
Feb 27
2021
|
Wilhelmus Cm Groenhuysen Chief Operating Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
7,715
+4.88%
|
$1,149,535
$149.1 P/Share
|
|
Feb 27
2021
|
Frank X Leonard EVP, Pres., Novocure Oncology |
BUY
Exercise of conversion of derivative security
|
Direct |
1,465
+1.73%
|
$218,285
$149.1 P/Share
|
|
Feb 27
2021
|
Ashley Cordova Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
1,465
+5.03%
|
$218,285
$149.1 P/Share
|
|
Feb 27
2021
|
Todd Christopher Longsworth General Counsel |
BUY
Exercise of conversion of derivative security
|
Direct |
5,555
+7.85%
|
$827,695
$149.1 P/Share
|
|
Feb 27
2021
|
Asaf Danziger Chief Executive Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
9,259
+4.28%
|
$1,379,591
$149.1 P/Share
|
|
Feb 27
2021
|
Pritesh Shah Chief Growth Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
3,086
+3.22%
|
$459,814
$149.1 P/Share
|
|
Feb 22
2021
|
Uri Weinberg Chief Innovation Officer |
SELL
Open market or private sale
|
Direct |
6,500
-19.06%
|
$1,137,500
$175.5 P/Share
|
|
Feb 22
2021
|
Uri Weinberg Chief Innovation Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
6,500
+16.01%
|
$45,500
$7.15 P/Share
|
|
Jan 15
2021
|
Todd Christopher Longsworth General Counsel |
SELL
Open market or private sale
|
Direct |
63,814
-2.94%
|
$11,039,822
$173.61 P/Share
|
|
Jan 15
2021
|
Todd Christopher Longsworth General Counsel |
BUY
Exercise of conversion of derivative security
|
Direct |
36,396
+22.77%
|
$509,544
$14.37 P/Share
|
|
Jan 06
2021
|
Asaf Danziger Chief Executive Officer |
BUY
Grant, award, or other acquisition
|
Direct |
53
+0.03%
|
$2,650
$50.67 P/Share
|
|
Jan 06
2021
|
Wilhelmus Cm Groenhuysen Chief Operating Officer |
BUY
Grant, award, or other acquisition
|
Direct |
93
+0.07%
|
$4,650
$50.67 P/Share
|
|
Dec 21
2020
|
Ely Benaim Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
2,484
-4.02%
|
$387,504
$156.71 P/Share
|
|
Dec 21
2020
|
Ely Benaim Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
2,484
+3.84%
|
$161,460
$65.43 P/Share
|
|
Dec 18
2020
|
Asaf Danziger Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
207,910
-3.55%
|
$33,265,600
$160.5 P/Share
|
|
Dec 18
2020
|
Asaf Danziger Chief Executive Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
207,910
+25.63%
|
$4,574,020
$22.0 P/Share
|
|
Dec 18
2020
|
Jeryl L Hilleman |
SELL
Open market or private sale
|
Direct |
2,500
-42.37%
|
$415,000
$166.4 P/Share
|
|
Nov 02
2020
|
Ashley Cordova Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
230
-0.87%
|
$26,910
$117.41 P/Share
|
|
Oct 29
2020
|
Pritesh Shah Chief Growth Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
30,468
+11.13%
|
$335,148
$11.1 P/Share
|
|
Feb 28
2020
|
Wilhelmus Cm Groenhuysen Chief Operating Officer |
SELL
Open market or private sale
|
Direct |
3,670
-2.39%
|
$264,240
$72.22 P/Share
|